An Open-label, Fixed-dose, Clinical Study of Quinacrine Safety and Efficacy in the Treatment of Advanced Renal Cell Carcinoma
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2015
At a glance
- Drugs Mepacrine (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Sponsors Cleveland BioLabs
- 31 Jul 2015 Planned End Date changed from 1 Dec 2009 to 1 Jan 2008 as reported by ClinicalTrials.gov record.
- 01 Feb 2008 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 07 Dec 2006 New trial record.